Structural Modification of the Designer Stimulant α-Pyrrolidinovalerophenone (α-PVP) Influences Potency at Dopamine Transporters

ACS Chemical Neuroscience

Volumn 6, Issue 10, 2015, Pages 1726-1731

  Kolanos, R ^a   Sakloth, F ^a   Jain, A D ^a   Partilla, J S ^b   Baumann, M H ^b   Glennon, R A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

DAT; dopamine transporter; flakka; serotonin transporter; SERT; Synthetic cathinones; PBP; PPP; PVP

Indexed keywords

1 PHENYL 2 (PIPERIDIN 1 YL)PENTAN 1 ONE HYDROCHLORIDE; 1 PHENYL 2 (PYRROLIDIN 1 YL)HEXANONE OXALATE; 2 (1 PYROLIDINYL) 1 ACETOPHENONE OXALATE; 2 (PYRROLIDIN 1 YL) 3,4 DIHYDRONAPHTHALEN 1(2H) ONE OXALATE; 2 BROMO 2 CYCLOHEXYL 1 PHENYLETHANONE; 2 BROMO 2 CYCLOPENTYL 1 PHENYLETHANONE; 2 CYCLOHEXYL 1 PHENYL 2 (PYRROLIDIN 1 YL)ETHANONE HYDROCHLORIDE; 2 CYCLOPENTYL 1 PHENYL 2 (PYRROLIDIN 1 YL)ETHANONE HYDROCHLORIDE; DESIGNER DRUG; DOPAMINE; DOPAMINE TRANSPORTER; PYRROLIDINE DERIVATIVE; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; ALPHA-PYRROLIDINOVALEROPHENONE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG INHIBITION; DRUG POTENCY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE; STRUCTURE ACTIVITY RELATION; ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECTS; MALE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRITIUM;

EID: 84945947790     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.5b00160     Document Type: Article

References (33)

1. UNODC (2013) The challenge of new psychoactive substances. United Nations Office on Drugs and Crime, World Drug Report. pp 1-108.
2. USDOJ (2013) U. S. Department of Justice Drug Enforcement Administration National Drug Threat Assessment Summary. DEA-NWW-DIR-017-13, pp 1-18.
3. UNODC (2014) United Nations Office on Drugs and Crime, World Drug Report. pp 1-93.
4. Glennon, R. A. (2014) Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention Adv. Pharmacol. 69, 581-620 10.1016/B978-0-12-420118-7.00015-9
5. Baumann, M. H., Partilla, J. S., and Lehner, K. R. (2013) Psychoactive 'bath salts': Not so soothing Eur. J. Pharmacol. 698, 1-5 10.1016/j.ejphar.2012.11.020
6. Baumann, M. H., Ayestas, M. A., Partilla, J. S., Sink, J. R., Shulgin, A. T., Daley, P. F., Brandt, S. D., Rothman, R. B., Ruoho, A. E., and Cozzi, N. V. (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue Neuropsychopharmacology 37, 1192-1203 10.1038/npp.2011.304
7. Spiller, H. A., Ryan, M. L., Weston, R. G., and Jansen, J. (2011) Clinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States Clin. Toxicol. 49, 499-505 10.3109/15563650.2011.590812
8. Baumann, M. H., Partilla, J. S., Lehner, K. R., Thorndike, E. B., Hoffman, A. F., Holy, M., Rothman, R. B., Goldberg, S. R., Lupica, C. R., Sitte, H. H., Brandt, S. D., Tella, S. R., Cozzi, N. V., and Schindler, C. W. (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products Neuropsychopharmacology 38, 552-562 10.1038/npp.2012.204
9. Cameron, K., Kolanos, R., Verkariya, R., De Felice, L., and Glennon, R. A. (2013) Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of 'bath salts,' produce opposite effects at the human dopamine transporter Psychopharmacology 227, 493-499 10.1007/s00213-013-2967-2
10. Cameron, K. N., Kolanos, R., Solis, E., Glennon, R. A., and De Felice, L. J. (2013) Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter Br. J. Pharmacol. 168, 1750-1757 10.1111/bph.12061
11. Eshleman, A. J., Wolfrum, K. M., Hatfield, M. G., Johnson, R. A., Murphy, K. V., and Janowsky, A. (2013) Substituted methcathinones differ in transporter and receptor interactions Biochem. Pharmacol. 85, 1803-1815 10.1016/j.bcp.2013.04.004
12. Simmler, L. D., Buser, T. A., Donzelli, M., Schramm, Y., Dieu, L.-H., Huwyler, J., Chaboz, S., Hoener, M. C., and Liechti, M. E. (2013) Pharmacological characterization of designer cathinones in vitro Br. J. Pharmacol. 168, 458-470 10.1111/j.1476-5381.2012.02145.x
13. Kolanos, R., Solis, E., Sakloth, F., De Felice, L. J., and Glennon, R. A. (2013) 'Deconstruction' of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter ACS Chem. Neurosci. 4, 1524-1529 10.1021/cn4001236
14. Aarde, S. M., Creehan, K. M., Vandewater, S. A., Dickerson, T. J., and Taffe, M. A. (2015) In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentio- phenone and 3,4-methylenedioxypyrovalerone: Self-administration and locomotor stimulation in male rats Psychopharmacology (Berlin) 232, 3045 10.1007/s00213-015-3944-8
15. Marusich, J. A., Antonazzo, K. R., Wiley, J. L., Blough, B. E., Partilla, J. S., and Baumann, M. H. (2014) Pharmacology of novel synthetic stimulants structurally related to the 'bath salts' constituent 3,4-methylenedioxypyrovalerone (MDPV) Neuropharmacology 87, 206-213 10.1016/j.neuropharm.2014.02.016
16. Kaizaki, A., Tanaka, S., and Numazawa, S. (2014) New recreational drug 1-phenyl-2(-1pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron J. Toxicol. Sci. 39, 1-6 10.2131/jts.39.1
17. Watterson, L. R. and Olive, M. F. (2014) Synthetic cathinones and their rewarding and reinforcing effects in rodents Adv. Neurosci. (Hindawi) 2014, 209875 10.1155/2014/209875
18. Naylor, J. E., Freeman, K. B., Blough, B. E., Woolverton, W. L., and Huskinson, S. L. (2015) Discriminative-stimulus effects of second generation synthetic cathinones in methamphetamine-trained rats Drug Alcohol Depend. 149, 280-284 10.1016/j.drugalcdep.2015.02.002
19. Federal Register (2014) Schedules of controlled substances: Temporary placement of 10 synthetic cathinones into Schedule I, Vol (March 7, 2014) 79, pp 12938-12943.
20. Durman, J., Grayson, J. I., Hunt, P. G., and Warren, S. (1986) Synthesis of α-phenylthio enones and esters of α-phenylthio alkenoic acids J. Chem. Soc., Perkin Trans. 1 1939-1946 10.1039/p19860001939
21. Thomae, K. (1963) α-Pyrrolidino ketones. U.K. Patent GB 933507, August 8.
22. Meltzer, P. C., Butler, D., Deschamps, J. R., and Madras, B. K. (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors J. Med. Chem. 49, 1420-1432 10.1021/jm050797a
23. Cattaneo, A., Gelmi, G., Jori, A., and Zevio, H. (1962) Some new compounds showing activity on the central nervous system Farmaco, Ed. Sci. 17, 308-314
24. Nishimura, H. and Takamatsu, H. (1964) Phenyl mercaptoalkylamines. I. (1964) 1-Phenyl-2(/or 3)-amino-alkanethiol derivatives Yakugaku Zasshi 84, 797-805
25. Seeger, E. and Riss, B. (1966) Compositions and methods for stimulating central nervous system and increasing the blood pressure. U.S. Patent 3,287,217, November 22.
26. Boswell, G. W., Musso, D. L., Kelley, J. L., Soroko, F. E., and Cooper, B. R. (1996) Synthesis and anti-tetrabenazine activity of C-3 analogues of dimethyl-2-phenylmorpholines J. Heterocycl. Chem. 33, 33-40 10.1002/jhet.5570330106
27. Welvart, Z. (1960) Modification of the reactivity of organomagnesium compounds. Orientation of their action on α-aminonitriles towards the formation of α-aminoketones Compt. Rend. 250, 1870-1872
28. Prokopowicz, M., Młynarz, P., and Kafarski, P. (2009) Synthesis of phosphonate derivatives of 2,3-dihydroindene Tetrahedron Lett. 50, 7314-7317 10.1016/j.tetlet.2009.10.042
29. Wamser, C. C. and Wagner, W. R. (1981) Type II photoelimination from α-cycloalkylacetophenones and a polystyrene-bound analogue J. Am. Chem. Soc. 103, 7232-7234 10.1021/ja00414a032
30. Frey, B., Hufton, R., Harding, M., and Draffan, A. G. (2013) Compounds for the treatment of HCV. International Patent WO2013036994 A1, March 21.
31. Lazer, E. S., Miao, C. K., Wong, H-Ch., Sorcek, R., Spero, D. M., Gilman, A., Pal, K., Behnke, M., Graham, A. G., Watrous, J. M., Homon, C. A., Nagel, J., Shah, A., Guindon, Y., Farina, P. R., and Adams, J. (1994) Benzoxazolamines and benzothiazolamines: Potent, enantioselective inhibitors of leukotriene biosynthesis with a novel mechanism of action J. Med. Chem. 37, 913-923 10.1021/jm00033a008
32. Hansch, C., Leo, A., Unger, S. H., Kim, K. H., Nikaitani, D., and Lien, E. J. (1973) Aromatic' substituent constants for structure-activity correlations J. Med. Chem. 16, 1207-1216 10.1021/jm00269a003
33. Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., and Partilla, J. S. (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 39, 32-41 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3